Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) Featured in Coverage of Investor Summit Group’s Q1 Virtual Event
Lobe Sciences (OTCQB: LOBEF) (CSE: LOBE) is a life sciences company focused on developing sub-psychedelic doses of psychedelic medicines targeting the 5-HT2A receptor. The company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds in conjunction with NAC (N-acetyl cysteine) to improve brain and mental health and wellness. Phil Young, CEO will provide an overview, scientific focus & development…